{"entity":{"type":"insider","cik":"0001740029","url":"/insider/0001740029","json_url":"/insider/0001740029.json","name":"BIOS Incysus Co-Invest I, LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":6,"first":"2022-08-17","last":"2022-12-13","span_basis":"filed_date"},"name_variants":[{"name":"BIOS Incysus Co-Invest I, LP","source":"filing","n_filings":6,"first_seen":"2022-08-17","last_seen":"2022-12-13"}],"transactions":[{"id":6476643,"accession":"0001104659-22-126432","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-126432","line_url":"/filing/0001104659-22-126432","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"Fletcher Aaron G.L.; BIOS Capital Management, LP; BIOS Incysus Co-Invest I, LP; BIOS Advisors GP, LLC; BIOS Fund II, LP; BIOS Fund II NT, LP; BIOS Fund III QP, LP; BIOS Fund II QP, LP; BIOS Fund III NT, LP; BIOS Fund III, LP","owner_display_name":"Fletcher Aaron G.L.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75001.0,"shares_display":"75,001","price_per_share":2.4788,"price_display":"2.48","price_state":"stated","total_value":185912.4788,"total_display":"185,912.48","total_whole":"185,912","shares_owned_after":3727597.0,"shares_owned_after_display":"3,727,597","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-12","filed_date":"2022-12-13","scope":"insider","n_lines":3},{"id":6462121,"accession":"0001104659-22-103860","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-103860","line_url":"/filing/0001104659-22-103860","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"BIOS Fund III QP, LP; BIOS Incysus Co-Invest I, LP; BIOS Fund III, LP; BIOS Fund II NT, LP; BIOS Capital Management, LP; BIOS Advisors GP, LLC; Fletcher Aaron G.L.; BIOS Fund II, LP; BIOS Fund II QP, LP; BIOS Fund III NT, LP","owner_display_name":"BIOS Fund III QP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":2.0214,"price_display":"2.02","price_state":"stated","total_value":50535.0,"total_display":"50,535.00","total_whole":"50,535","shares_owned_after":3670545.0,"shares_owned_after_display":"3,670,545","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-28","filed_date":"2022-09-29","scope":"insider","n_lines":3},{"id":6462065,"accession":"0001104659-22-095839","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-22-095839","line_url":"/filing/0001104659-22-095839","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"BIOS Equity Partners III, LP; BIOS Incysus Co-Invest I, LP; BIOS Fund II NT, LP; Cavu Advisors, LLC; Bios Equity Partners II, LP; Cavu Management, LP; Kreis Leslie W.; BIOS Fund II QP, LP; BIOS Fund II, LP","owner_display_name":"BIOS Equity Partners III, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":2.02,"price_display":"2.02","price_state":"stated","total_value":80800.0,"total_display":"80,800.00","total_whole":"80,800","shares_owned_after":3651528.0,"shares_owned_after_display":"3,651,528","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-29","filed_date":"2022-08-30","scope":"insider","n_lines":3},{"id":6150805,"accession":"0001104659-22-095951","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-22-095951","line_url":"/filing/0001104659-22-095951","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"BIOS Fund II QP, LP; Cavu Advisors, LLC; Fletcher Aaron G.L.; BIOS Equity Partners III, LP; BIOS Incysus Co-Invest I, LP; Cavu Management, LP; Bios Equity Partners II, LP; BIOS Fund II, LP; BIOS Fund II NT, LP","owner_display_name":"BIOS Fund II QP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":2.02,"price_display":"2.02","price_state":"stated","total_value":80800.0,"total_display":"80,800.00","total_whole":"80,800","shares_owned_after":3651528.0,"shares_owned_after_display":"3,651,528","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-29","filed_date":"2022-08-30","scope":"insider","n_lines":3},{"id":6462055,"accession":"0001104659-22-095839","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-095839","line_url":"/filing/0001104659-22-095839","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"BIOS Equity Partners III, LP; BIOS Incysus Co-Invest I, LP; BIOS Fund II NT, LP; Cavu Advisors, LLC; Bios Equity Partners II, LP; Cavu Management, LP; Kreis Leslie W.; BIOS Fund II QP, LP; BIOS Fund II, LP","owner_display_name":"BIOS Equity Partners III, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11214.0,"shares_display":"11,214","price_per_share":2.01,"price_display":"2.01","price_state":"stated","total_value":22540.14,"total_display":"22,540.14","total_whole":"22,540","shares_owned_after":3621100.0,"shares_owned_after_display":"3,621,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-26","filed_date":"2022-08-30","scope":"insider","n_lines":3},{"id":6150796,"accession":"0001104659-22-095951","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-095951","line_url":"/filing/0001104659-22-095951","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"BIOS Fund II QP, LP; Cavu Advisors, LLC; Fletcher Aaron G.L.; BIOS Equity Partners III, LP; BIOS Incysus Co-Invest I, LP; Cavu Management, LP; Bios Equity Partners II, LP; BIOS Fund II, LP; BIOS Fund II NT, LP","owner_display_name":"BIOS Fund II QP, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11214.0,"shares_display":"11,214","price_per_share":2.01,"price_display":"2.01","price_state":"stated","total_value":22540.14,"total_display":"22,540.14","total_whole":"22,540","shares_owned_after":3621100.0,"shares_owned_after_display":"3,621,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-26","filed_date":"2022-08-30","scope":"insider","n_lines":3},{"id":6927911,"accession":"0001104659-22-092685","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-092685","line_url":"/filing/0001104659-22-092685","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"Kreis Leslie W.; Cavu Management, LP; Cavu Advisors, LLC; BIOS Equity Partners III, LP; BIOS Incysus Co-Invest I, LP; BIOS Fund II QP, LP; Bios Equity Partners II, LP; BIOS Fund II, LP; BIOS Fund II NT, LP","owner_display_name":"Kreis Leslie W.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":1.93,"price_display":"1.93","price_state":"stated","total_value":96500.0,"total_display":"96,500.00","total_whole":"96,500","shares_owned_after":3612569.0,"shares_owned_after_display":"3,612,569","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-17","filed_date":"2022-08-18","scope":"insider","n_lines":3},{"id":6110025,"accession":"0001104659-22-092057","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-092057","line_url":"/filing/0001104659-22-092057","is_derivative":false,"issuer_cik":"0001714576","issuer_name":"IN8BIO, INC.","issuer_ticker":"INAB","issuer_name_source":null,"issuer_url":"/issuer/0001714576","owner_cik":null,"owner_name":"Bios Equity Partners II, LP; Cavu Advisors, LLC; BIOS Fund II, LP; BIOS Fund II NT, LP; Kreis Leslie W.; BIOS Incysus Co-Invest I, LP; BIOS Fund III QP, LP; BIOS Equity Partners III, LP; Cavu Management, LP","owner_display_name":"Bios Equity Partners II, LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1773684.0,"shares_display":"1,773,684","price_per_share":1.9,"price_display":"1.90","price_state":"stated","total_value":3369999.6,"total_display":"3,369,999.60","total_whole":"3,370,000","shares_owned_after":3574534.0,"shares_owned_after_display":"3,574,534","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-16","filed_date":"2022-08-17","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001740279","name":"IN8BIO, INC.","url":"/issuer/0001740279","role":"Director, Ten percent owner","n_filings":6,"first_seen":"2022-08-17","last_seen":"2022-12-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001740029","retrieved_at":"2026-08-23T00:57:09+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}